For example, the VIOLETTE study (NCT03330847) in patients with mTNBC investigated the use of olaparib as 2/3L therapy, or combining olaparib with other molecular targeted drugs, such as ceralasertib (an ATR inhibitor), as has been proposed for ovarian cancer [45, 46]. The gene discussed is ATR; the disease is ovarian cancer.